midas2 (Q117334)
From MaRDI portal
 | This is the item page for this Wikibase entity, intended for internal use and editing purposes. Please use this page instead for the normal view: midas2 |
Bayesian Platform Design with Subgroup Efficacy Exploration(MIDAS-2)
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | midas2 |
Bayesian Platform Design with Subgroup Efficacy Exploration(MIDAS-2) |
Statements
14 July 2023
0 references
The rapid screening of effective and optimal therapies from large numbers of candidate combinations, as well as exploring subgroup efficacy, remains challenging, which necessitates innovative, integrated, and efficient trial designs(Yuan, Y., et al. (2016) <doi:10.1002/sim.6971>). MIDAS-2 package enables quick and continuous screening of promising combination strategies and exploration of their subgroup effects within a unified platform design framework. We used a regression model to characterize the efficacy pattern in subgroups. Information borrowing was applied through Bayesian hierarchical model to improve trial efficiency considering the limited sample size in subgroups(Cunanan, K. M., et al. (2019) <doi:10.1177/1740774518812779>). MIDAS-2 provides an adaptive drug screening and subgroup exploring framework to accelerate immunotherapy development in an efficient, accurate, and integrated fashion(Wathen, J. K., & Thall, P. F. (2017) <doi:10.1177/1740774517692302>).
0 references
0 references
0 references
